BACKGROUND: The benefits of using thin acetabular components for hip resurfacing have been shown in terms of bone conservation, but there currently are little data available in the literature addressing the mid-term clinical results of these devices. QUESTIONS/PURPOSES: We aimed to determine whether thinner acetabular components altered mid-term postoperative clinical scores, complication rates, survivorship, radiographic appearance, and metal ion levels. METHODS: Two hundred eighty-one patients with unilateral disease received a 5-mm thick acetabular shell and 223 received a 3.5-mm shell. The femoral component implanted in both groups was identical. We compared clinical scores, complication rates, survivorship, radiographic results, and ion levels between these two groups. RESULTS: UCLA hip scores were similar (pain, p = 0.0976; walking, p = 0.9571; function, p = 0.9316; activity, p = 0.2085). Complications were higher in the 5-mm group (6.4% versus 1.8%, p = 0.0431). Both groups were similar regarding survivorship (p = 0.3181), cup radiolucency at 5 years (p = 0.107), and metal ion levels (cobalt p = 0.404, chromium p = 0.250). CONCLUSIONS: With comparable mid-term clinical results, there is no tangible reason to abstain from using the 3.5-mm acetabular component. LEVEL OF EVIDENCE: Level III, retrospective comparative study. See the Guidelines for Authors for a complete description of levels of evidence.
BACKGROUND: The benefits of using thin acetabular components for hip resurfacing have been shown in terms of bone conservation, but there currently are little data available in the literature addressing the mid-term clinical results of these devices. QUESTIONS/PURPOSES: We aimed to determine whether thinner acetabular components altered mid-term postoperative clinical scores, complication rates, survivorship, radiographic appearance, and metal ion levels. METHODS: Two hundred eighty-one patients with unilateral disease received a 5-mm thick acetabular shell and 223 received a 3.5-mm shell. The femoral component implanted in both groups was identical. We compared clinical scores, complication rates, survivorship, radiographic results, and ion levels between these two groups. RESULTS: UCLA hip scores were similar (pain, p = 0.0976; walking, p = 0.9571; function, p = 0.9316; activity, p = 0.2085). Complications were higher in the 5-mm group (6.4% versus 1.8%, p = 0.0431). Both groups were similar regarding survivorship (p = 0.3181), cup radiolucency at 5 years (p = 0.107), and metal ion levels (cobalt p = 0.404, chromium p = 0.250). CONCLUSIONS: With comparable mid-term clinical results, there is no tangible reason to abstain from using the 3.5-mm acetabular component. LEVEL OF EVIDENCE: Level III, retrospective comparative study. See the Guidelines for Authors for a complete description of levels of evidence.
Authors: Paul R Kim; Paul E Beaulé; Michael Dunbar; Joshua K L Lee; Nicholas Birkett; Michelle C Turner; Nagarajkumar Yenugadhati; Vic Armstrong; Daniel Krewski Journal: J Bone Joint Surg Am Date: 2011-05 Impact factor: 5.284
Authors: James P Yoon; Michel J Le Duff; Alicia J Johnson; Karren M Takamura; Edward Ebramzadeh; Harlan C Amstutz Journal: Clin Orthop Relat Res Date: 2012-11-27 Impact factor: 4.176
Authors: Inari Kostensalo; Mika Junnila; Petri Virolainen; Ville Remes; Markus Matilainen; Tero Vahlberg; Pekka Pulkkinen; Antti Eskelinen; Keijo T Mäkelä Journal: Acta Orthop Date: 2013-06-25 Impact factor: 3.717